Page 227«..10 20..226227228 229..240 250..»

Category Archives: Stem Cells

Cramer Chronicles: Can This Marriage Be Saved?, Part 1 – Video

Posted: December 15, 2012 at 9:45 pm

Cramer Chronicles: Can This Marriage Be Saved?, Part 1
At the carriage house, Rex and Gigi brainstormed together about how to get their hands on Stacy #39;s cache of stem cells. Rex posited that Shane #39;s leukemia might return. Gigi was alarmed until Rex reassured her that Shane would not actually become ill, but that they would let Stacy believe that Shane had relapsed. He suggested that once Stacy believed that Shane was sick again, she would retrieve the blood, and Rex would find it and bust her for good. They resolved to tell Shane the truth in order to bring him into their plan, but Gigi asked Rex what they would tell him about their having gotten back together. Schuyler arrived at the rehab center with flowers for his co-worker, Rachel. He revealed that Shaun had left the flowers. The two talked about the Evans brothers and Morasco sisters. Schuyler admitted that whatever his feelings for Gigi, a part of him would always love the Stacy he remembered from Las Vegas. As the two left the rehab center together, Rachel offered to take Schuyler to lunch. At the Palace Hotel, the Evans siblings met for lunch. Destiny was delighted as Greg gave her a new cell phone, but Shaun was unimpressed, and accused Greg of trying to buy their sister #39;s love after skipping out on their dinner date. Before long, Greg got a call from Dr. Wright and told Destiny that Matthew #39;s test results were in. Destiny was dying to know Matthew #39;s prognosis, but Greg told her he had to speak to the family first, and bid his brother and sister farewell. In an exam ...From:dia1962Views:4 0ratingsTime:09:53More inEntertainment

Continue reading here:
Cramer Chronicles: Can This Marriage Be Saved?, Part 1 - Video

Posted in Stem Cells | Comments Off

Cramer Chronicles: Can This Marriage Be Saved?, Part 4 – Video

Posted: December 15, 2012 at 9:44 pm

Cramer Chronicles: Can This Marriage Be Saved?, Part 4
At the carriage house, Rex and Gigi brainstormed together about how to get their hands on Stacy #39;s cache of stem cells. Rex posited that Shane #39;s leukemia might return. Gigi was alarmed until Rex reassured her that Shane would not actually become ill, but that they would let Stacy believe that Shane had relapsed. He suggested that once Stacy believed that Shane was sick again, she would retrieve the blood, and Rex would find it and bust her for good. They resolved to tell Shane the truth in order to bring him into their plan, but Gigi asked Rex what they would tell him about their having gotten back together. Schuyler arrived at the rehab center with flowers for his co-worker, Rachel. He revealed that Shaun had left the flowers. The two talked about the Evans brothers and Morasco sisters. Schuyler admitted that whatever his feelings for Gigi, a part of him would always love the Stacy he remembered from Las Vegas. As the two left the rehab center together, Rachel offered to take Schuyler to lunch. At the Palace Hotel, the Evans siblings met for lunch. Destiny was delighted as Greg gave her a new cell phone, but Shaun was unimpressed, and accused Greg of trying to buy their sister #39;s love after skipping out on their dinner date. Before long, Greg got a call from Dr. Wright and told Destiny that Matthew #39;s test results were in. Destiny was dying to know Matthew #39;s prognosis, but Greg told her he had to speak to the family first, and bid his brother and sister farewell. In an exam ...From:dia1962Views:3 0ratingsTime:09:05More inEntertainment

Read the original post:
Cramer Chronicles: Can This Marriage Be Saved?, Part 4 - Video

Posted in Stem Cells | Comments Off

Cramer Chronicles: Can This Marriage Be Saved?, Part 2 – Video

Posted: December 15, 2012 at 9:44 pm

Cramer Chronicles: Can This Marriage Be Saved?, Part 2
At the carriage house, Rex and Gigi brainstormed together about how to get their hands on Stacy #39;s cache of stem cells. Rex posited that Shane #39;s leukemia might return. Gigi was alarmed until Rex reassured her that Shane would not actually become ill, but that they would let Stacy believe that Shane had relapsed. He suggested that once Stacy believed that Shane was sick again, she would retrieve the blood, and Rex would find it and bust her for good. They resolved to tell Shane the truth in order to bring him into their plan, but Gigi asked Rex what they would tell him about their having gotten back together. Schuyler arrived at the rehab center with flowers for his co-worker, Rachel. He revealed that Shaun had left the flowers. The two talked about the Evans brothers and Morasco sisters. Schuyler admitted that whatever his feelings for Gigi, a part of him would always love the Stacy he remembered from Las Vegas. As the two left the rehab center together, Rachel offered to take Schuyler to lunch. At the Palace Hotel, the Evans siblings met for lunch. Destiny was delighted as Greg gave her a new cell phone, but Shaun was unimpressed, and accused Greg of trying to buy their sister #39;s love after skipping out on their dinner date. Before long, Greg got a call from Dr. Wright and told Destiny that Matthew #39;s test results were in. Destiny was dying to know Matthew #39;s prognosis, but Greg told her he had to speak to the family first, and bid his brother and sister farewell. In an exam ...From:dia1962Views:2 0ratingsTime:08:04More inEntertainment

Excerpt from:
Cramer Chronicles: Can This Marriage Be Saved?, Part 2 - Video

Posted in Stem Cells | Comments Off

BioLife Solutions Announces TiGenix’s Completion of Stem Cells and HypoThermosol® Clinical Trial

Posted: December 15, 2012 at 9:44 pm

BOTHELL, Wash., Dec. 12, 2012 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today announced that its customer TiGenix NV (Euronext Brussels: TIG) has completed a phase I clinical safety trial of its expanded adipose-derived stem cell platform incorporating BioLife's cGMP HypoThermosol cell/tissue storage/shipping medium.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

The clinical trial, titled "Phase I Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs)," assessed the safety, tolerability and feasibility of a potential cell-based therapy TiGenix is developing for a number of autoimmune disorders including rheumatoid arthritis.

Eduardo Bravo, TiGenix CEO, remarked on the selection of HypoThermosol as a combination shipping medium and vehicle solution for TiGenix's stem cell technology, "HypoThermosol allows us to increase the stability profile of our clinical cell-based products and considerably extends their shelf-life. Increased shelf-life of cell therapy products will be key in future commercial distribution."

Mike Rice, BioLife Solutions Chief Executive Officer, said, "We want to congratulate TiGenix on this important milestone. They join a growing list of regenerative medicine companies that have adopted our best in class biopreservation media products in the development of their clinical cell and tissue based therapies. We're very pleased to support their clinical product development."

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol and CryoStor platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

See more here:
BioLife Solutions Announces TiGenix's Completion of Stem Cells and HypoThermosol® Clinical Trial

Posted in Stem Cells | Comments Off

Two More Editorials: The California Stem Cell Agency Should Heed IOM Recommendations for Reform

Posted: December 14, 2012 at 9:15 pm

Two other major California newspapers
today said the $3 billion California stem cell agency needs to “clean
up its act” if it wants to be successful in continuing its efforts
at turning stem cells into cures.

The editorials appeared in the Los Angeles
Times, the state's largest circulation newspaper at more than
700,000, and the San Jose Mercury News in California's Silicon Valley.
The Mercury News has a reported circulation of nearly 600,000,
although that figure includes other Bay Area newspaper owned by the
same chain.

Both editorials focused on the 17-month evaluation of the agency by the prestigious Institute of Medicine (IOM) as did earlier editorials in The Sacramento Bee and the San Francisco Chronicle. The IOM recommended sweeping reforms at the agency that would alter its structure and target conflicts of interest.

The Times said,

“The $700,000 spent on the
study...will be wasted if the institute's oversight board fails to
heed the (IOM) committee's
criticisms, which echo the findings of the Little Hoover
Commission and other groups over the years.”

The editorial continued,

“The 29-member board is made up
almost entirely of representatives of advocacy groups and research
institutions that have a direct interest in how the money is spent.”

The Times cited the California Stem
Cell Report's calculations that about 90 percent of the $1.7 billion awarded by CIRM has gone to institutions linked to current and former members of its governing board.

The Times noted an award to a Northern California firm that has stirred some criticism. The editorial said,

“The board also overrode the advice
of its scientific advisors — twice on a single application when it
considered a grant for a well-connected company, StemCells Inc. based
in Newark, Calif. The board granted the company $20 million after Robert Klein, the driving force behind the passage of Proposition 71,
which created and funded the agency in 2004, and its former head,
lobbied so intensively for the company that one board member
described it as 'arm-twisting.'"

The Times concluded,

“The agency has used more than half
of its funding and one day will almost certainly want to ask
taxpayers for more. It should remember that voters will look for
evidence of public accountability as well as respected research.”

The San Jose paper sounded a similar
note about the agency. Its editorial said,

“(I)f it wants to survive...it
should heed the Institute of Medicine's advice to eliminate conflicts
of interest on its board -- and do it before awarding the remaining
$1.2 billion of the $3 billion voters approved for stem cell
research.”

But the paper said the stem cell agency
should not be provided any more state funding.

“Long-term funding was never the
intent when Proposition 71 passed in 2004. It was supposed to
kick-start research at a time when federal funding was blocked and to
establish California as a major player in the rapidly advancing
medical field.

“The agency could continue to bring
value to the state as an advocate and funder of research, but only if
it can attract private donors, partners and investors. For that to
happen, it will need a board that passes the ethics test, with more
independent experts and industry executives free of conflicts.

“At the outset, stem cell advocates
took immense pride in structuring the agency to keep it relatively
free of legislative interference despite the use of public money.
Politicians kept their hands off, which was good. But the agency
created its own inappropriate influences in the way it constituted
its board. Now it needs to clean up its act.“

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/hjDmQPb6wDs/two-more-editorials-california-stem.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Meager Coverage of Yesterday's Bristling IOM-CIRM Meeting

Posted: December 13, 2012 at 8:31 pm

Mainstream news coverage today was skimpy, to put it mildly, of the testy session yesterday involving the governing board of the California stem
cell agency and representatives of the prestigious Institute of
Medicine(IOM).

Only two pieces appeared, one in the
San Diego U-T and another on the web site of the Los Angeles Times. Both
discussed what the Michael Hiltzik of the Times column called “overt hostility” on the
part of several board members (see yesterday's item here). Bradley
Fikes of the San Diego paper said the patient advocates on the board
“strongly criticized” the IOM report on the grounds that it
“unfairly suggests that they have a conflict of interest.”

One of the recommendations of the IOM
is that the agency develop ways to manage personal conflicts of
interest dealing with patient advocates and others at the agency.

Fikes wrote,

"'I'm a
colon cancer survivor,' said Art Torres, vice chairman of the
oversight committee, and a patient advocate designate. 'Does having
colon cancer make me biased?'
“Jeff
Sheehy, another patient advocate designate, protested what he called
a 'defenestration' of patient advocates, whose interests often span
multiple diseases.”

Ron Leuty of the San Francisco Business
Times skipped the IOM matter and wrote about the awarding of $36
million in grants. However, a list of the most popular stories on the
Business Times web site, ranked as No. 5 Leuty's story last week on the IOM
study, just below an article about Stanford's $111 million
concert hall.

Fikes also had a piece on ViaCyte,
which is in his area, receiving another $3 million from CIRM.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/sTuRbsA7d_w/meager-coverage-of-yesterdays-bristling.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Appeals at the California Stem Cell Agency: Worthwhile or Worthless?

Posted: December 13, 2012 at 3:56 pm

Jon Shestack, a patient advocate member
of the governing board of the California stem cell agency, weighed in
today on the virtues of the grant application appeal process at the
$3 billion research enterprise.

His remarks came in a “comment”
filed on the Duchenne item that appeared yesterday on this site. (His
full comment can be found at the end of that item.)

Shestack said that the handling of the
$6 million CIRM grant involving Duchenne research is “a casebook
study on why the special(extraordinary) petition is worthwhile. There
was indeed new and relevant information that only became available
after grant review. Scientific staff and leadership flagged it.”

The utility of the petitions is one of
the reasons that we ran the story about Duchenne and the team at
UCLA. The extraordinary petition process is currently under fire by
both the Institute of Medicine and the stem cell agency itself, which
has appointed a task force to come up with changes. But, while the
petition process is certainly less than perfect, so is the peer
review/grant review process.

The Duchenne application is not the
only “case study.” An application by Karen Aboody of the City of
Hope is often cited as another case. There are undoubtedly others.

The petition process was adopted
several years ago by the board as a tool to manage willy-nilly
appearances of scientists before the CIRM governing board whose
applications were rejected by reviewers. Now the Institute of
Medicine has recommended the petitions be abandoned, saying they
undermine the integrity of grant review process. The IOM cited a
major controversy in Texas involving its cancer research agency as an
example of how grant reviews or the lack of them can go bad – not
to mention conflict of interest problems there. CIRM has already
started to look for better solutions regarding appeals. Many of its directors
are troubled by emotional presentations from patients in
connection with petitions and the lack of adequate information to
make informed decisions on the spot about the contested matters.

Whether appeals can be put in a tidy,
scientific box is debatable. Researchers have the right, under state
law, to address the board on any issue whatsoever. And at least some
of them will continue to do so -- regardless of any appeals changes -- when millions of dollars and their
careers are at stake.

Opinions and decisions of CIRM
reviewers are not holy writ. They can and do make mistakes, as we
all do. In making changes in the appeals process, the goal of the
agency should be to devise a public and transparent process rather
than enshroud it in more secrecy. CIRM also should find a way to do
a much better job of communicating to applicants the availability of
appeals and precisely how to appeal when it becomes necessary.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/ROhqJSUEC28/appeals-at-california-stem-cell-agency.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

BioLife Solutions Announces TiGenix’s Completion of Stem Cells and HypoThermosolÂ® Clinical Trial

Posted: December 13, 2012 at 7:51 am

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

About TiGenix

About BioLife Solutions

Continued here:
BioLife Solutions Announces TiGenix's Completion of Stem Cells and HypoThermosolÂ® Clinical Trial

Posted in Stem Cells | Comments Off

Research and Markets: Global Stem Cells Pipeline Capsule – 2012

Posted: December 13, 2012 at 7:51 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/557jct/global_stem_cells) has announced the addition of the "Global Stem Cells Pipeline Capsule - 2012" report to their offering.

Fore Pharma's latest report 'Global Stem Cells Pipeline Capsule - 2012' provides up-to-date information on key Research and Development activities (R&D) in the global stem cells market. It covers active stem cells pipeline molecules in various stages of clinical trials, preclinical research, and drug discovery.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating opportunities, formulating business development strategies, executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the R&D stages. It also provides information on pipeline molecules developed in leading geographies (North America and Europe). Licensing activities are thoroughly captured in this report.

Key Features of the Report:

- Stem Cells: Overview

- Stem Cells Pipeline Overview

- Stem Cells Phase 3 Clinical Trial Pipeline Insights

- Stem Cells Phase 2 Clinical Trial Pipeline Insights

See original here:
Research and Markets: Global Stem Cells Pipeline Capsule - 2012

Posted in Stem Cells | Comments Off

LA Times: On the California Stem Cell Agency and Wasting $700,000

Posted: December 13, 2012 at 12:04 am

The headline on the Los Angeles
Times web site this afternoon read,

"Is California's stem cell program
preparing to waste $700,000?"

The question was raised by Pulitzer
Prize-winning columnist Michael Hiltzik, whowas commenting on the presentation today by the
prestigious Institute of Medicine's (IOM) on its sweeping
recommendations for changes at the state stem cell agency.

Hiltzik wrote,

"If you're betting that
the California
stem cell agency will spurn key recommendations of a
blue-ribbon review panel that criticized its leadership and
management structures, you might want to double that bet. Several
board members showed overt hostility to the panel's recommendations
during a public meeting today."

Harold Shapiro, chairman of the IOM
panel and former president of Princeton University, delivered
the briefing. The group's study took 17 months and cost the stem cell
agency $700,000.

Hiltzik's piece summarized the IOM
proposals, which echoed many criticisms that have been aired for
years in California. Hiltzik wrote,

"CIRM Chairman Jonathan
Thomas glided over those issues when he introduced Shapiro.
Thomas observed that the Institute of Medicine report included many
statements "validating CIRM, its process, what it was able to
achieve," which is a bit like launching the investigation of a
plane crash by focusing on all the planes that land safely every day.
Thomas did mention that the Institute of Medicine had made numerous
recommendation about how to "take something which is already a
great experience and improve it even further."

"Shapiro got only a few minutes
into his presentation before board members started interrupting him
with objections to the Institute of Medicine's recommendation for a
majority of independent members."

Hiltzik concluded,

"Thomas promised to stage a public
workshop on the Institute of Medicine report soon and to subject them
to 'lengthy discussion.'

"Does that sound as if the board
will be taking seriously the advice that it change the way it does
business? Stay tuned, but don't hold your breath."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/9CY8_m5Reqo/la-times-on-california-stem-cell-agency.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Page 227«..10 20..226227228 229..240 250..»

Category Archives: Stem Cells

Cramer Chronicles: Can This Marriage Be Saved?, Part 1 – Video

Cramer Chronicles: Can This Marriage Be Saved?, Part 4 – Video

Cramer Chronicles: Can This Marriage Be Saved?, Part 2 – Video

BioLife Solutions Announces TiGenix’s Completion of Stem Cells and HypoThermosol® Clinical Trial

Two More Editorials: The California Stem Cell Agency Should Heed IOM Recommendations for Reform

Meager Coverage of Yesterday's Bristling IOM-CIRM Meeting

Appeals at the California Stem Cell Agency: Worthwhile or Worthless?

BioLife Solutions Announces TiGenix’s Completion of Stem Cells and HypoThermosolÂ® Clinical Trial

Research and Markets: Global Stem Cells Pipeline Capsule – 2012

LA Times: On the California Stem Cell Agency and Wasting $700,000

Categories

Archives

Recommended Sites

Contact Us

Recent Posts